What is PRIME?

PRIME is a European consortium of research institutes, medical centres, companies, and societal stakeholders that is funded through an EU Horizon 2020 grant. From 2020 – 2024, PRIME will aim to unravel the insulin-dependent mechanisms that underly both somatic conditions (i.e. type 2 diabetes, obesity, metabolic syndrome) and brain disorders (i.e. Alzheimer’s disease, obsessive-compulsive disorder, autism spectrum disorders). Until now, very little attention has been paid to the role of insulin signaling in brain disorders, and the overlap (or ‘multimorbidity’) with somatic conditions.

Therefore, through PRIME, we aim to develop tools for improved diagnosis, clinical care and prevention of insulin-related lifespan multimorbidity.

Learn More

News & Events

12 July 2022

Interview with Dr. Janita Bralten on ‘Insulinopathies of the brain? Genetic overlap between somatic insulin-related and neuropsychiatric disorders’

As part of the ‘Research in Practice in Mental Health’ series, Dr. Janita Bralten recently gave an interview talking about PRIME’s work on the genetic overlap between somatic disorders and brain-based disorders. To hear the full interview, please click here.

More News